



## Kiadis Pharma expands presence in the United States

January 4, 2019

### Kiadis Pharma expands presence in the United States

*Scott Holmes commences position as chief financial officer  
Amy Sullivan appointed senior vice president, corporate affairs  
Both are based in Boston, Massachusetts*

**Amsterdam, The Netherlands, and Boston, Massachusetts, USA - January 4, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS)**, a clinical-stage biopharmaceutical company, today announces that it has expanded its presence in the United States. Two of Kiadis' key interfaces for the financial markets are now based in Boston, with the previously [announced](#) appointment of Scott Holmes as chief financial officer and today's announcement of Amy Sullivan as senior vice president of corporate affairs, both effective January 1, 2019. Ms. Sullivan will replace Karl Hård, who resigned effective December 31<sup>st</sup> to pursue other interests.

**Arthur Lahr, CEO of Kiadis Pharma, commented:** "I would like start by thanking Karl for his service to Kiadis and wishing him well in all his future endeavors. I am excited to officially welcome both Scott and Amy to our company. They are a strong team and together bring a wealth of capital markets experience and strong relationships with the financial community to our company. I look forward to working with them as we continue to raise awareness of Kiadis within the financial markets, as well as the medical community, in both the US and Europe."

Ms. Sullivan is a seasoned corporate affairs professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Ms. Sullivan joins Kiadis from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmaceuticals and Genencor International. Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University.

Along with Mr. Holmes, Ms. Sullivan will be based in Boston. She will be responsible for investor relations, corporate communications and public affairs for Kiadis.

#### For more information, please contact:

**Kiadis Pharma:**

Amy Sullivan, SVP, Corporate Affairs  
Tel. +1 508 479 3480  
[a.sullivan@kiadis.com](mailto:a.sullivan@kiadis.com)

**Optimum Strategic Communications:**

Mary Clark, Supriya Mathur, Hollie Vile  
Tel: +44 203 714 1787  
David Brillleslijper (Amsterdam)  
Tel: +31 610 942 514  
[kiadis@optimumcomms.com](mailto:kiadis@optimumcomms.com)

#### About Kiadis Pharma

Kiadis Pharma is developing its lead product candidate, ATIR101, for use in conjunction with haploidentical HSCT for adult blood cancers to address key limitations of haploidentical HSCT, without prophylactic immunosuppression and its associated morbidity and mortality. Based on the positive results from the single dose Phase II CR-AIR-007 study, the Company submitted a marketing authorization application to the European Medicines Agency in April 2017 for approval of ATIR101 as an adjunctive treatment in haploidentical HSCT for high risk adult hematological malignancies. If the product is conditionally approved, Kiadis Pharma intends to launch ATIR101 in selected countries in Europe through its own commercial organization starting in the second half of 2019.

In December 2017, Kiadis Pharma commenced an international, multicenter, randomized and controlled Phase III clinical trial of ATIR101 against the Post-Transplant Cyclophosphamide, or PTCy protocol, the main protocol used to perform a haploidentical HSCT. The trial will be performed in 250 patients with acute leukemia and myelodysplastic syndrome at approximately 50 sites in the United States, Canada, Europe and certain additional countries. ATIR101 received regenerative medicine advanced therapy designation from the FDA in September 2017, which provides benefits that are materially equivalent to a breakthrough designation from the FDA. In addition, ATIR101 has been granted multiple orphan drug designations both in the European Union and the United States.

The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.

#### **Forward Looking Statements**

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*